Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias

Inclusion Criteria: * Male, female, non-gender conforming patients aged \>18 years with symptomatic anemia attributed to chronic gastrointestinal blood loss from angioectasias despite endoscopic ablation and iron therapy * Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: * Contraindications to tranexamic acid (TXA) therapy * Allergy to TXA, intracranial bleed, history of venous or arterial thromboembolism, active thromboembolic disease, ischemic retinopathy * Bleeding/Coagulopathy disorder and/or on anticoagulation regimen * Ulcerative colitis or Crohn's disease * End stage renal disease * Decompensated cirrhosis * Pregnancy or intention to become pregnant * Patient refusal of blood products because the secondary outcome is pre-determined * Unable to give formal consent * Participation in another interventional study where primary outcome includes hemoglobin/hematocrit values * Inability to adhere to treatment regimen for 3 months * Non-English speaking * Patients \< 18 years old